Ro 5-3335

Product Description

Ro 5-3335 is a core binding factor (CBF) inhibitor; preferentially kills human leukemia cell lines with CBF fusion proteins (IC₅₀ = 1.1 μM). Represses RUNX1/CBFβ-dependent transactivation in reporter assays and inhibits transcriptional regulation by RUNX1 and CBFβ. Reduces leukemia burden in a mouse model. Attenuates RUNX1-dependent hematopoiesis in zebrafish embryos. Also a Tat antagonist; inhibits HIV-1 replication in vitro.

Solubility

Preparing Stock Solutions for Ro 5-3335

The following data is based on the product molecular weight 259.69

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

4 3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.85 mL	19.25 mL	38.51 mL
5 mM	0.77 mL	3.85 mL	7.70 mL
10 mM	0.39 mL	1.93 mL	3.85 mL
50 mM	0.08 mL	0.39 mL	0.77 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Cupelli The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter. J.Virol. 1995 PMID: 7884917
• Okuda RUNX1/AML1: a central player in hematopoiesis. Int. J. Hematol. 2001 PMID: 11721959
• Cunningham Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBF beta interaction. Proc.Natl.Acad.Sci.USA 2012 PMID: 22912405